Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19.

Autor:	Qiu J; Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona, USA., Engelbrektson A; Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona, USA., Song L; Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona, USA., Park J; Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona, USA., Murugan V; Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona, USA., Williams S; Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona, USA., Chung Y; Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona, USA.; College of Health Solutions, Arizona State University, Phoenix, Arizona, USA., Pompa-Mera EN; Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.; Hospital de Infectología, CMN 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico., Sandoval-Ramirez JL; Hospital de Infectología, CMN 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico., Mata-Marin JA; Hospital de Infectología, CMN 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico., Gaytan-Martinez J; Hospital de Infectología, CMN 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico., Troiani E; Università Cattolica del Sacro Cuore, Rome, Italy., Sanguinetti M; Università Cattolica del Sacro Cuore, Rome, Italy.; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Roncada P; Department of Health Sciences, University Magna Græcia of Catanzaro, Catanzaro, Italy., Urbani A; Università Cattolica del Sacro Cuore, Rome, Italy.; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Moretti G; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Torres J; Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico., LaBaer J; Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona, USA.
Jazyk:	angličtina
Zdroj:	Microbiology spectrum [Microbiol Spectr] 2023 Aug 17; Vol. 11 (4), pp. e0469022. Date of Electronic Publication: 2023 Jun 06.
DOI:	10.1128/spectrum.04690-22
Abstrakt:	Patients with 2019 coronavirus disease (COVID-19) exhibit a broad spectrum of clinical presentations. A person's antimicrobial antibody profile, as partially shaped by past infection or vaccination, can reflect the immune system health that is critical to control and resolve the infection. We performed an explorative immunoproteomics study using microbial protein arrays displaying 318 full-length antigens from 77 viruses and 3 bacteria. We compared antimicrobial antibody profiles between 135 patients with mild COVID-19 disease and 215 patients with severe disease in 3 independent cohorts from Mexico and Italy. Severe disease patients were older with higher prevalence of comorbidities. We confirmed that severe disease patients elicited a stronger anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) response. We showed that antibodies against HCoV-229E and HcoV-NL63 but not against HcoV-HKU1 and HcoV-OC43 were also higher in those who had severe disease. We revealed that for a set of IgG and IgA antibodies targeting coronaviruses, herpesviruses, and other respiratory viruses, a subgroup of patients with the highest reactivity levels had a greater incidence of severe disease compared to those with mild disease across all three cohorts. On the contrary, fewer antibodies showed consistent greater prevalence in mild disease in all 3 cohorts. IMPORTANCE The clinical presentations of COVID-19 range from asymptomatic to critical illness that may lead to intensive care or even death. The health of the immune system, as partially shaped by past infections or vaccinations, is critical to control and resolve the infection. Using an innovative protein array platform, we surveyed antibodies against hundreds of full-length microbial antigens from 80 different viruses and bacteria in COVID-19 patients from different geographic regions with mild or severe disease. We not only confirmed the association of severe COVID-19 disease with higher reactivity of antibody responses to SARS-CoV-2 but also uncovered known and novel associations with antibody responses against herpesviruses and other respiratory viruses. Our study represents a significant step forward in understanding the factors contributing to COVID-19 disease severity. We also demonstrate the power of comprehensive antimicrobial antibody profiling in deciphering risk factors for severe COVID-19. We anticipate that our approach will have broad applications in infectious diseases. Competing Interests: The authors declare no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu